Nasdaq · Healthcare

Cue Biopharma, Inc. (CUE)

As-reported financials and recent SEC filings for Cue Biopharma, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$27.5M

Net income

$-26.6M

Net margin

-96.9%

Diluted EPS

$-0.28

ROE

-100.6%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$27.5M	$9.3M	$5.5M	$1.2M	$14.9M
Gross profit	—	—	—	—	—
Operating income	$-26.6M	$-41.5M	$-52.1M	$-53.2M	$-43.7M
Net income	$-26.6M	$-40.7M	$-50.7M	$-53.0M	$-44.2M
Diluted EPS	$-0.28	$-0.72	$-1.11	$-1.49	$-1.41

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

EFFECT2026-07-01

S-32026-06-18

EFFECT2026-06-17

32026-06-11

32026-06-11

42026-06-08

32026-06-08

42026-06-03

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on CUE

Search Cue Biopharma, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.